<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65264">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672138</url>
  </required_header>
  <id_info>
    <org_study_id>TANTRA_TCAI</org_study_id>
    <nct_id>NCT01672138</nct_id>
  </id_info>
  <brief_title>Pulmonary Vein Antrum Isolation (PVAI) Plus Isolation of Complex Fractionated Atrial Electrograms (CAFE) and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation</brief_title>
  <acronym>TANTRA</acronym>
  <official_title>PVAI Plus Isolation of CAFEs and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Cardiac Arrhythmia Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Pacific Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Cardiac Arrhythmia Research Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to examine the long-term success rate of catheter ablation in non-paroxysmal
      atrial fibrillation patients using different ablation strategies such as 1) PVAI alone, 2)
      PVAI+ CFAE, 3) PVAI+ CFAE+ non-PV trigger ablation.

      [ PVAI: Pulmonary Vein Antrum Isolation CFAE: Complex Fractionated Atrial Electrograms
      Non-PV triggers: Triggers arising from sites other than pulmonary veins]
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Back ground: Pulmonary vein antrum isolation (PVAI) as a lone procedure, is known to have
      limited success rate in terms of long-term recurrence-free survival in non-paroxysmal atrial
      fibrillation (NPAF) and additional ablations isolating extra-PV triggers seem to improve the
      outcome (1). The extra-PV triggers include complex fractionated atrial electrograms (CFAEs)
      and triggers from other sites such as left atrial posterior wall, superior vena cava, left
      atrial appendage, ligament of Marshall and coronary sinus (1, 2). These are known to be
      independent predictors of late AF recurrence following catheter ablation (3, 4, and 5). In a
      meta-analysis of several studies comparing long-term efficacy of different ablation
      strategies, Li et al have reported superior success rate of combined CFAE ablation and
      standard PVAI in maintaining long-term sinus-rhythm (6). Similarly, earlier studies have
      demonstrated better ablation outcome in NPAF when non-PV triggers sites were isolated along
      with PVAI (5, 7). However, limited data is available showing a comparison of the lasting
      efficacy of the above three procedures when used in different combinations.

      Hypothesis: The combined ablation strategy including PVAI, ablation of CFAE and extra-PV
      triggers has the highest likelihood of maintaining long-term sinus rhythm in patients with
      NPAF.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence of atrial arrhythmia</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any episode of AF/AT (atrial tachycardia) longer than 30 seconds will be considered as recurrence). Episodes that occur during the first 3 months of the procedure (blanking period) will not be considered as recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in quality of life</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">186</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <condition>Long-standing Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pulmonary Vein Antrum Isolation alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PVAI+ CFAE ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PVAI + CFAE + non-PV triggers ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Vein Antrum Isolation</intervention_name>
    <description>Radio-frequency catheter ablation of pulmonary vein antrum</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Study I</arm_group_label>
    <arm_group_label>Study II</arm_group_label>
    <other_name>PVAI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CFAE ablation</intervention_name>
    <description>Catheter ablation of CFAEs</description>
    <arm_group_label>Study I</arm_group_label>
    <arm_group_label>Study II</arm_group_label>
    <other_name>CFAE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Isolation of non-PV triggers</intervention_name>
    <description>Catheter ablation of triggers originating from extra-PV sites</description>
    <arm_group_label>Study II</arm_group_label>
    <other_name>Non-PV triggers ablation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years

          2. Patients presenting with drug-refractory long-standing persistent AF (LSPAF)

          3. Ability to understand and provide signed informed consent

        Exclusion Criteria:

          1. Previous catheter ablation or MAZE procedure in left atrium

          2. Reversible causes of atrial arrhythmia such as hyperthyroidism, sarcoidosis,
             pulmonary embolism etc
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Natale, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TCAI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Natale, MD</last_name>
    <email>dr.natale@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luigi Di Biase, MD PhD</last_name>
    <email>dibbia@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. david's medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luigi Di Biase, MD</last_name>
      <email>dibbia@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mitra Mohanty, MD</last_name>
      <email>mitra1989@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac arrhythmia Institute, St. David's Hospital</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Natale, MD</last_name>
      <phone>512-544-8186</phone>
      <email>dr.natale@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>June 4, 2013</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Cardiac Arrhythmia Research Foundation</investigator_affiliation>
    <investigator_full_name>Andrea Natale</investigator_full_name>
    <investigator_title>Executive medical director, TCAI</investigator_title>
  </responsible_party>
  <keyword>PVAI</keyword>
  <keyword>CFAE</keyword>
  <keyword>NPAF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
